Pathstone Holdings
RPRX icon

Pathstone Holdings’s Royalty Pharma RPRX Stock Holding History

Pathstone Holdings’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.07M Buy
54,725
+3,716
+7% +$193K 0.01% 883
2026
Q1 		$2.45M Buy
51,009
+3,354
+7% +$147K 0.01% 924
2025
Q4 		$1.84M Sell
47,655
-485
-1% -$18.5K 0.01% 1067
2025
Q3 		$1.7M Sell
48,140
-69
-0.1% -$2.5K 0.01% 1128
2025
Q2 		$1.74M Buy
48,209
+23,188
+93% +$768K 0.01% 1082
2025
Q1 		$779K Buy
25,021
+14,980
+149% +$475K ﹤0.01% 1506
2024
Q4 		$256K Sell
10,041
-11,965
-54% -$317K ﹤0.01% 2042
2024
Q3 		$623K Buy
22,006
+2,467
+13% +$68.3K ﹤0.01% 1626
2024
Q2 		$515K Buy
19,539
+76
+0.4% +$2.11K ﹤0.01% 1671
2024
Q1 		$591K Buy
19,463
+6,971
+56% +$206K ﹤0.01% 1602
2023
Q4 		$352K Buy
+12,492
New +$343K ﹤0.01% 1720

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Pathstone Holdings's RPRX Position: Q2 2026 in Review

Pathstone Holdings increased its Royalty Pharma (RPRX) stake by 7.3% in Q2 2026, buying an estimated $193K and bringing the position to 54,725 shares worth $3.07M. The position accounts for 0.01% of the portfolio, ranked #883.

Pathstone Holdings first reported a position in RPRX in Q4 2023 and has held it in 11 quarters since. 643 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Pathstone Holdings held 54,725 shares of Royalty Pharma worth $3.07M as of Q2 2026.
  • Pathstone Holdings bought 3,716 Royalty Pharma shares in Q2 2026, an estimated $193K.
  • Royalty Pharma made up 0.01% of Pathstone Holdings's portfolio in Q2 2026, its #883 holding.
  • Pathstone Holdings first reported a position in Royalty Pharma in Q4 2023 and has held it in 11 quarters since.
  • 643 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Pathstone Holdings's 13F filing for Q2 2026, filed 13 Aug 2026.